• Home
  • NEW DAY MEDICINE
  • 3 (77) 2025
  • 116 -3 (77) 2025 - Kadirov Sh.Sh., Xakimova G.G. - COMPARISON OF SYSTEMIC AND LOCAL IMMUNITY INDICATORS IN THE TREATMENT OF STOMACH CANCER PATIENTS

116 -3 (77) 2025 - Kadirov Sh.Sh., Xakimova G.G. - COMPARISON OF SYSTEMIC AND LOCAL IMMUNITY INDICATORS IN THE TREATMENT OF STOMACH CANCER PATIENTS

COMPARISON OF SYSTEMIC AND LOCAL IMMUNITY INDICATORS IN THE TREATMENT OF STOMACH CANCER PATIENTS

Kadirov Sh.Sh. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Xakimova G.G. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Xakimov G.A. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Saloxiddinov X.A. - Tashkent Pediatric Medical Institute

Urmonov U.B. - Tashkent Pediatric Medical Institute, Tashkent city branch of the Republican specialized scientific and practical center of oncology and radiology

Resume

Purpose. To study the state of systemic immunity and local immunity before and during chemotherapy in patients with gastric adenocarcinoma. Materials and methods. From 2017 to 2018 at the N.N.Blokhin NMRC of oncology 20 primary metastatic patients with gastric adenocarcinoma received chemotherapy. The sampling of biological material (peripheral blood, tumor tissue) was carried out twice (before treatment and during the first control examination, after 3 courses). The percentage of the degree of infiltration of tumor tissue by lymphocytes (CD45+CD14-TILs) was estimated by flow cytometry; T cells (CD3+CD19-TILs); B cells (CD3-CD19+TILs); NK cells (CD3-CD16+CD56+TILs); CD16 and CD8 effector cells and their cytotoxic potential (CTP) (CD16+Perforin+TILs; CD16CTPTILs), (CD8+Perforin+TILs; CD8CTPTILs); regulatory T cells - NKT cells (CD3+CD16+CD56+TILs), CD4 (CD4+CD25+CD127-TILs) and CD8 (CD8+CD11b-CD28-TILs) regulatory cells and these parameters of systemic results. The factor of a favorable prognosis for PFS in patients with metastatic gastric cancer in the peripheral blood was an increase in the number of CD8 + T-regulatory cells (5.1% - 12.1%, p = 0.019), and in tumor tissue - an increase in the perforin potential of effector CD16 cells (0.5% - 4.9%, p = 0.030) and their cytotoxic potential (13.2% - 55.7%, p = 0.011). When assessing the changes in the indices of local immunity during chemotherapy, it was noted a negative effect of an increase of T cells (22.0% - -9.7%, p = 0.012), NKT - cells (207.9% - -13.8%, p = 0.002) and CD4 + T-regulatory cells (190.7% - -25.2%, p = 0.002). In contrast, an increase in the level of effector CD16 cells during chemotherapy increases the likelihood of surviving PFS - 9 months (-69.5% - 9.1%, p = 0.013). Conclusion. Indicators of local and systemic immunity serve as additional prognostic factors for gastric cancer.

Key words: metastatic stomach cancer; cellular immunity; local immunity, chemotherapy.

First page

657

Last page

666

For citation:Kadirov Sh.Sh., Xakimova G.G., Xakimov G.A., Saloxiddinov X.A., Urmonov U.B. - COMPARISON OF SYSTEMIC AND LOCAL IMMUNITY INDICATORS IN THE TREATMENT OF STOMACH CANCER PATIENTS//New Day in Medicine 3(77)2025 657-666 https://https://newdayworldmedicine.com/en/new_day_medicine/3-77-2025

List of References

  1. Wu, Y. Clinical significance of peripheral blood and tumor tissue lymphocyte subsets in cervical cancer patients / Y. Wu, S. Ye, S. Goswami et al. / BMC Cancer. 2020;20(1):173.
  2. Каприн А. Д., Старинский В. В., Шахзадова О.А. Состояние Онкологической Помощи Населению России. В 2021 Году 2022; 236 стр.
  3. Sung H., Ferlay J., Siegel R.L. et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021;71:209-49. DOI: 10.3322/caac.21660
  4. Megan Spafford, Danley Lunn, Peter Graham, Malignant inflammatory myofibroblastic tumor: a rare case presentation, Journal of Surgical Case Reports, Volume 2022, Issue 9, September 2022, rjac403, https://doi.org/10.1093/jscr/rjac403
  5. Бережная Н.М. Взаимодействие клеток системы иммунитета с другими компонентами микроокружения. Онкология. 2009;1(2):86-93.
  6. Mantovani A. et al. Tumor immunity: effector response to tumor and role of the microenvironment. Lancet 2008;371(9614):771-83.
  7. Тупицын Н.Н. Иммунофенотип рака молочной железы. В кн.: Рак молочной железы. Под ред. Н.Е. Кушлинского, С.М. Портного, К.П. Лактионова. М.: Издательство РАМН, 2005; 174-97 стр.
  8. Balch C., Riley L., Bae T. et al. Patterns of human tumor infiltrating lymphocytes in 120 human cancers. Arch Surg 1990;125(2):200-205.
  9. Galon J., Pages F. et al. Cancer classification using the immunoscore: a worldwide task force. J Transl Med 2012;10:205.
  10. Zamarron B.F., Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci. 2011;7(5):651-658.
  11. Ruffell B., DeNardo D.G., Affara N.I. et al. Lymphocytes in cancer development: polarization towards protumor immunity. Cytokine Growth Factor Rev. 2010;21:3-10.
  12. Shen Z. Zhou S., Wang Y. et al. Higher intratumoral infiltrated Foxp3+ Treg numbers and Foxp3+/C8+ ratio are associated with adverse prognosis in resectable gastric cancer. J Cancer Res Clin. Oncol. 2010;136:1585-1595.
  13. Zheng X., Song X., Shao Y. et al. Prognostic role of tumor-infiltrating lymphocytes in gastric cancer: A meta-analysis. Oncotarget. 2017;8/10.18632/oncotarget.18065.
  14. He Q. et al. Impact of the immune cell population in peripheral blood on response and survival in patients receiving neoadjuvant chemotherapy for advanced gastric cancer / Q. He, G. Li, X. Ji et al. // Tumor Biology. 2017;39(5):e.101042831769757.
  15. Заботина Т.Н. Особенности субпопуляционного состава лимфоцитов периферической крови и инфильтрирующих опухоль у больных плоскоклеточным раком головы и шеи / Т.Н. Заботина, А.И. Черткова, В.Т. Циклаури и др. // Иммунология. 2019;40(3):10-19.
  16. Loi, S. Prognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy / S. Loi et al. // J Clin Oncol. 2013;31:860-7.
  17. Murta, E.F. Lymphocyte subpopulations in patients with advanced breast cancer submitted to neoadjuvant chemotherapy / E.F. Murta, J.M. de Andrade et al. // Tumori. 2000;86(5):403-7.
  18. Chang, W.C. Clinical significance of regulatory T cells and CD8+ effector populations in patients with human endometrial carcinoma / W.C. Chang, C.H. Li, S.C. Huang et al. // Cancer. 2010;116:5777-5788.
  19. Gao Q. Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection / Q. Gao, S.J. Qiu, J. Fan et al. // J Clin Oncol. 2007;25:2586-2593.
  20. Ormandy, L.A. Increased populations of regulatory T-cells in peripheral blood of patients with hepatocellular carcinoma / L.A. Ormandy, T. Hillemann, H. Wedemeyer et al. // Cancer Res. 2005;65:2457-2464.

    file

    download